Background. In a previous randomized trial of voriconazole versus amphotericin B deoxycholate for primary therapy of invasive aspergillosis, voriconazole demonstrated superior efficacy and better survival. In that trial, treatment with voriconazole or amphotericin B deoxycholate could be followed with other licensed antifungal therapies (OLAT). Here, we report the impact of OLAT on the outcome of patients with invasive aspergillosis.
Background. In a previous randomized trial of voriconazole versus amphotericin B deoxycholate for primary therapy of invasive aspergillosis, voriconazole demonstrated superior efficacy and better survival. In that trial, treatment with voriconazole or amphotericin B deoxycholate could be followed with other licensed antifungal therapies (OLAT). Here, we report the impact of OLAT on the outcome of patients with invasive aspergillosis.
Methods. Data on dose, duration, and the reason for switching to the first OLAT were analyzed, and outcome at week 12 was assessed.
Results. Fewer patients in the voriconazole group (52 [36%] of 144) switched to OLAT, compared with patients in the amphotericin B deoxycholate group (107 [80%] of 133). Lipid formulations of amphotericin B were the most common OLAT (38% of patients). Switches were made because of intolerance or insufficient response in 70% for patients in the amphotericin B deoxycholate group, compared with 24% of patients in the voriconazole group. Favorable responses to OLAT in the amphotericin B deoxycholate group occurred in only 19% of patients with initial insufficient response and 38% of patients with intolerance. Salvage therapy with a lipid formulation of amphotericin B after initial treatment with amphotericin B deoxycholate was successful for only 30% of patients (14 of 47). Treatment success among patients randomized to receive amphotericin B, including those whose treatment was switched to OLAT, was 32%, compared with 55% among patients who received voriconazole alone ( ). P ! .001 Conclusions. This study highlights the limited efficacy of salvage antifungal therapy, including therapy with lipid formulations of amphotericin B, and demonstrates the importance of effective initial therapy in invasive aspergillosis.
In a prospective, randomized trial of the strategy of following voriconazole or amphotericin B deoxycholate with other licensed antifungal therapy for primary treatment of invasive aspergillosis, the voriconazole regimen demonstrated superior efficacy and a 22% relative survival benefit [1] . Investigators were allowed to follow amphotericin B deoxycholate or voriconazole therapy with other licensed antifungal therapy that was deemed to be most appropriate for each patient. Switches to other licensed antifungal therapy were allowed in cases of insufficient clinical response or intolerance, as well as for long-term suppression after completion of initial randomized therapy.
After that trial, voriconazole received regulatory approval for primary therapy of invasive aspergillosis and has been recommended for use as initial therapy for persons with this disease [2, 3] . In contrast, other antifungal agents, including lipid formulations of amphotericin B, have been studied for use as salvage therapy (i.e., for patients with drug intolerance or insufficient clinical response) and are approved by the US Food and Drug Administration for use only in such circumstances for invasive aspergillosis. In this study, we analyzed the outcomes of patients with invasive aspergillosis who received initial treatment with voriconazole or amphotericin B deoxycholate that was followed by other licensed antifungal therapy, focusing on the impact of other licensed therapy.
PATIENTS AND METHODS
The patient database generated from the Global Comparative Aspergillosis Study was used to identify patients who were switched from initial randomized therapy to other licensed antifungal therapy at any time during the study [1] . Data on dose, duration, and the reason for switching to the first other licensed antifungal therapy were analyzed. Outcomes at week 12 were assessed, which was the primary assessment end point for the randomized trial. The planned duration of initial randomized therapy was 12 weeks, with an additional 4-week follow-up period. Reasons for switching to the first other licensed antifungal therapy were categorized as follows: intolerance, insufficient clinical response, or long-term suppression after completion of the initial randomized therapy, all of which were determined by the clinical investigator.
Patients who received initial randomized therapy for the duration of the study were also identified, and data on the duration of initial randomized therapy were collected. Treatment success at week 12 was defined as a complete or partial response to treatment, according to a composite assessment of global response by the blinded data review committee. Unsuccessful response to treatment was defined as stable disease or as global treatment failure, according to an assessment by the blinded data review committee. Evaluations of global responses were based on reviews of clinical, mycological, and radiological data [1] .
Initial randomized therapy (with voriconazole or amphotericin B deoxycholate) was discontinued for patients with severe adverse events, patients with an increase in the serum creatinine level to double the baseline value or to 13 mg/dL, and patients with an increase in aminotransferase levels to 15 times the upper limit of normal or to 10 times the upper limit of normal if the baseline value was 12 times the upper limit of normal. The primary efficacy analysis in the randomized trial was conducted on the modified intention-to-treat population, which consisted of patients with a data review committee-adjudicated diagnosis of definite or probable invasive aspergillosis who received at least 1 dose of study drug [1] . Assessments in the present study were performed on the same modified intention-to-treat population evaluated in the randomized trial. Statistical comparisons were made, when appropriate, using x 2 analysis (Epi Info; Centers for Disease Control and Prevention) and the Mann-Whitney U test (Epi Info) to compare durations of therapy. ). Successful outcomes with itraconazole P ! .001 as the other licensed antifungal were seen in 11 (65%) of 17 patients after initial voriconazole therapy and in 18 (50%) of 36 patients after amphotericin B deoxycholate therapy, which reflected the use of itraconazole as long-term suppressive therapy. Overall, 10 patients randomized to receive initial treatment with amphotericin B deoxycholate and 1 patient randomized In patients whose treatment was switched to other licensed antifungal therapy because of long-term suppression before the end of the evaluation period, successful responses occurred in 11 (79%) of 14 patients in the voriconazole group and in 6 (60%) of 10 patients in the amphotericin B deoxycholate group. Itraconazole was the most common antifungal agent received by these 24 patients.
RESULTS

Fifty
Overall, treatment success for patients randomized to receive initial amphotericin B deoxycholate, including those whose treatment was switched to other licensed antifungal therapy, occurred in 42 (32%) of 133, which was significantly less than the number of successful responses (51 [55%] of 92 patients) that occurred in the voriconazole group ( ). Fourteen P ! .001 (41%) of the 34 patients randomized to receive voriconazole whose first other licensed antifungal therapy was a polyene (amphotericin B deoxycholate or a lipid formulation of amphotericin B) had successful outcomes, compared with 24 (28%) of 87 patients randomized to receive amphotericin B deoxycholate who did not receive other licensed antifungals or whose first other licensed antifungal therapy was a polyene ( ) . P p .18
DISCUSSION
In this analysis, the limited efficacy of salvage therapy after initial treatment with amphotericin B deoxycholate was demonstrated. Notably, most other licensed antifungal therapies have been evaluated and approved for use as salvage therapy in patients with invasive aspergillosis. Overall, salvage therapy with lipid formulations of amphotericin B produced a favorable response in only 30%, but the success decreased to only 1 (12%) of 8 patients when lipid formulations of amphotericin B were used in patients after an initial insufficient clinical response to amphotericin B deoxycholate. The poor responses to initial amphotericin B deoxycholate seen in the clinical trial suggest that the strategy of using initial amphotericin B deoxycholate followed by rescue therapy with amphotericin B lipid formulations should not be recommended [4] .
As has been noted in studies with other antifungal agents, patients with intolerance to antifungal therapy had better responses than patients with progression of disease [5, 6] . Notably, better outcomes with initial voriconazole, compared with outcomes associated with initial amphotericin B deoxycholate therapy, were seen in patients intolerant of initial therapy, as well as in patients with insufficient clinical response, suggesting the importance of initial therapy for this disease. Additional changes in antifungal therapy after the first switch to other licensed antifungal therapy occurred for 46% of patients. In this analysis, we focused on the choice of the first other licensed antifungal therapy, because the initial switch reflected a problem with the initial randomized therapy.
Better responses occurred in the 24 patients (14 in the voriconazole group and 10 in amphotericin B deoxycholate group) who completed initial randomized therapy and received other licensed therapy as secondary prophylaxis before the end of the 16-week study evaluation period. It is not surprising that oral itraconazole was the most common agent selected as other licensed antifungal therapy in such cases and that favorable outcomes were observed in these patients.
The design of the randomized trial utilized amphotericin B deoxycholate as the comparator agent, which prohibited direct comparison of voriconazole and lipid formulations of amphotericin B as primary therapy. However, to assess the efficacy of therapy with voriconazole alone (i.e., without the impact of other licensed antifungal therapy), outcomes for patients who received only voriconazole were compared with outcomes for patients who received initial therapy with amphotericin B deoxycholate, with allowance for switches to other licensed antifungal therapy among patients in that arm of the study. On the basis of that assessment, it was observed that 55% of patients receiving voriconazole alone had favorable responses, which was significantly better than the rate of favorable responses associated with the strategy of initial therapy with amphotericin B deoxycholate followed by other licensed antifungal therapy, in which success occurred in only 32% of patients. The limited efficacy associated with polyene therapy in our study is consistent with results that were seen in the other large comparative trial of primary therapy for invasive aspergillosis, in which there were poor but equal responses to treatment with high doses of amphotericin B deoxycholate and a lipid formulation of amphotericin B [7] .
Only 1 patient (who had an unsuccessful outcome) received caspofungin as salvage therapy in this trial, because the study was conducted before regulatory approval of the echinocandins. However, in open, noncomparative trials involving salvage therapy with the echinocandins, success rates have ranged from 35% to 45%, which supports the conclusion of the limited success of rescue therapy for invasive aspergillosis [6, 8, 9] .
The theoretical possibility of antagonism after the sequential exposure of Aspergillus organisms to an azole followed by a polyene has been shown in some studies [10] [11] [12] . Because the rate of favorable outcomes for patients treated with voriconazole initially, followed by a polyene (41% of patients), was no worse than the rate for outcomes of treatment with polyene therapy only (28% of patients), there was no apparent antagonism with the sequential use of a polyene after initial voriconazole therapy.
CONCLUSIONS
This study highlights the limited efficacy of salvage antifungal therapy, including with lipid formulations of amphotericin B, and demonstrates the importance of effective initial therapy in the treatment of invasive aspergillosis.
